Synoptic reporting of echocardiography in carcinoid heart disease (ENETS Carcinoid Heart Disease Task Force). (26th November 2021)

• Record Type: Journal Article
• Authors: Hofland, Johannes; Lamarca, Angela; Steeds, Richard; Toumpanakis, Christos; Srirajaskanthan, Rajaventhan; Riechelmann, Rachel; Panzuto, Francesco; Frilling, Andrea; Denecke, Timm; Christ, Emanuel; Grozinsky‐Glasberg, Simona; Davar, Joseph
• Other Names: K Clift Ashley investigator.; Geilvoet Wanda investigator.; Grande Enrique investigator.; Pape Ulrich‐Frank investigator.; Prasad Vikas investigator.; van Velthuysen Marie‐Louise investigator.; Walter Thomas investigator.; Welin Staffan investigator.; de Herder Wouter W. guestEditor.; Fazio Nicola guestEditor.; O'Toole Dermot guestEditor.
• Is Part Of: Journal of neuroendocrinology. Volume 34:Number 3(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-11-26
• Subjects: carcinoid heart disease -- echocardiography -- neuroendocrine neoplasia -- synoptic reporting; Neuroendocrinology -- Periodicals; 616.4
• DOI: 10.1111/jne.13060
• Languages: English
• ISSNs: 0953-8194

Abstract

Abstract: Background: This European Neuroendocrine Tumor Society (ENETS) Expert Consensus document aims to provide practical guidance and standardization for echocardiography in the screening and follow‐up of carcinoid heart disease (CHD) in patients with a neuroendocrine tumour (NET) and carcinoid syndrome. Methods: NET experts within the ENETS Carcinoid Heart Disease Task Force reviewed both general reporting guidelines and specialized scoring systems for transthoracic echocardiography (TTE) in CHD. Based on this review, a dedicated template report was designed by the multidisciplinary working group of cardiologists, oncologists, endocrinologists, gastroenterologists, surgeons and radiologists. Results: We propose a Synoptic Reporting of Echocardiography in Carcinoid Heart Disease which represents an agreed peer reviewed proforma to capture information at the time of referral and enable a detailed outcome of CHD assessment. This includes a systematic and detailed list of structures to evaluate data to capture at the time of reporting of TTE. Conclusions: Adherence to these reporting guidelines aims to promote homogeneous and detailed evaluation of CHD to secure accurate assessment and allow comparison of studies performed intra‐ and inter‐individually. These guidelines could also facilitate CHD assessment as part of prospective clinical trials to enable standardization of the findings seen in response to therapy. Abstract : This guidelines aims to provide guidance for standardized reporting of echocardiography for the indication of screening or follow‐up of carcinoid heart disease.